13741-18-9|Xibornol|3,4-Xylenol, 6-isobornyl- (8CI)|-范德生物科技公司

Xibornol

NMR下载 COA and HPLC MSDS下载
names：
3,4-Xylenol, 6-isobornyl- (8CI)
CAS号：
13741-18-9
MDL Number：
MF(分子式)： C18H26O MW(分子量)： 258.405
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	3,4-Xylenol, 6-isobornyl- (8CI)
英文别名	Xibornol; CP-34; CP 34; CP34; Bactacine.
CAS号	13741-18-9
Inchi	InChI=1S/C18H26O/c1-11-8-14(16(19)9-12(11)2)15-10-13-6-7-18(15,5)17(13,3)4/h8-9,13,15,19H,6-7,10H2,1-5H3
InchiKey	RNRHMQWZFJXKLZ-UHFFFAOYSA-N
分子式 Formula	C18H26O
分子量 Molecular Weight	258.405
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Xibornol(CAS:13741-18-9):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Xibornol is a biochemical.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Zeh A, Planert M, Klima S, Hein W, Wohlrab D. The flexible Triac-Brace for conservative treatment of idiopathic scoliosis. An alternative treatment option? Acta Orthop Belg. 2008 Aug;74(4):512-2[1]PubMed PMID: 18811036.

[2]Cirri M, Mura P, Mora PC. Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems. Int J Pharm. 2007 Aug 1;340(1-2):84-91. Epub 2007 Mar 30. PubMed PMID: 17531411.

[3] Cairella M. [Active drugs in diseases of the respiratory system]. Clin Ter. 1988 Jul 15;126(1):67-9. Italian. PubMed PMID: 2973962.

[4] Fabbri A, Tacchella A, Belli ML. Activity of xibornol against Staphylococcus aureus. Chemioterapia. 1988 Apr;7(2):86-8. PubMed PMID: 3396117.

[5] Fraschini F, Scaglione F, Maierna G, Savio G, Gattei G, Falchi M. Non-interference of xibornol on the theophylline blood levels. Int J Clin Pharmacol Res. 1988;8(1):43-6. PubMed PMID: 3366502.

6: Scaglione F, Trazzi R, Odero A, Sambataro G, Savio G, Ferrara F, Fraschini F. Xibornol: multiple dose pharmacokinetics and diffusion in lung, tonsillar tissue and laryngeal mucosa. Int J Clin Pharmacol Res. 1988;8(6):457-61. PubMed PMID: 3253223.7: Combe J, Simonnet F, Simonnet G. [Action of xibornol on cell division and macromolecular synthesis of gram-positive bacterias]. Ann Pharm Fr. 1988;46(1):19-26. French. PubMed PMID: 3146238.8: Borzani M, Varotto F, Garlaschi L, Scotti G, Savio G. [Evaluation of the eradicating capacity of xibornol in pediatric pharyngeal carriers of beta-hemolytic streptococci and study of the interaction between the drug and the chemiluminescent activity of PMN leukocytes]. Minerva Pediatr. 1987 Jun 30;39(11-12):555-9. Italian. PubMed PMID: 3627066.9: De Mattia D, Santoro A, Grumo AR, Santoro N. [Xibornol in inflammatory involvement of the upper airways in childhood. A comparative clinical investigation]. Minerva Pediatr. 1986 Nov 15;38(21):1017-24. Italian. PubMed PMID: 3807837.10: Capristo AF, Maiello N, Coppola T, Decimo F, Miraglia del Giudice M Jr, Antignani RG. [Clinical evaluation of a new antibacterial agent, xibornol, in the treatment of bacterial infections of the upper respiratory tract in childhood. Comparison with erythromycin]. Minerva Pediatr. 1986 Jun 30;38(11-12):503-10. Italian. PubMed PMID: 3526110.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开